Intuitive Surgical: The Widest Gap Between Operations and Share Price in Years

Intuitive Surgical beats Q2 estimates but shares stay down 33% YTD. Tariffs, GLP-1 drugs, and cautious guidance overshadow strong da Vinci sales.

The stock market has a peculiar habit of punishing companies for the wrong reasons. Intuitive Surgical is living proof of that right now. The robotic surgery pioneer has delivered a quarter that beat analyst expectations on nearly every metric, yet its shares remain deep in negative territory for the year — down 33.88 percent since January 1.

Monday's bounce of 5.74 percent to 324.40 euros in German trading offered some relief, but the stock still sits 37.19 percent below its 52-week high reached on January 7. A day earlier, the shares had climbed 5.43 percent to 323.45 euros. The picture is clear: this is a stock in recovery mode, not yet in turnaround territory.

A Quarter That Should Have Silenced the Critics

The numbers from July 16 were hard to argue with. Second-quarter revenue climbed 18.4 percent to $2.89 billion, while earnings per share of $2.80 blew past the $2.48 consensus estimate. da Vinci procedure volumes grew 15 percent, and the company placed 468 new systems during the quarter — 246 of them the latest-generation da Vinci 5. The Ion endoscopy platform added 55 installations, a 21 percent increase that brought the installed base to 1,096 units.

So why the sell-off? The answer lies in guidance, not execution. Management reiterated its full-year 2026 forecast of 13.5 to 15.5 percent procedure growth — solid numbers, but a far cry from the double-digit expansion rates investors had grown accustomed to. The market wanted perfection and got something merely excellent.

The External Pressures Reshaping the Outlook

Two external forces are weighing on the procedure pipeline. GLP-1 weight-loss drugs are suppressing demand for bariatric surgeries by a high single-digit percentage, as patients increasingly opt for pharmacological solutions over surgical intervention. Separately, the approaching expiration of tax incentives in the U.S. healthcare system is making patients and providers hesitant about scheduling elective procedures.

Trade policy adds another layer of complexity. Roughly 80 percent of Intuitive's instruments are manufactured in Mexico and, without recourse to the USMCA agreement, would face a 25 percent tariff. The company is guiding to a 2026 gross margin of 68 to 69 percent, with the tariff impact of one percentage point already baked into that figure. A $28 million IEEPA reimbursement in the second quarter provided some offset, but the tariff overhang remains a persistent drag.

A Defensive Move That Speaks Volumes

On July 31, 2026, the board quietly amended the company's bylaws. The new rules tighten nomination requirements for shareholders, demanding that activist applicants mobilize 67 percent of outstanding shares — a formidable hurdle that effectively shields management from activist interference. It's a strategic decision that allows leadership to focus on the da Vinci 5 rollout rather than defensive battles with investors.

The buyback program reinforces that confidence. Intuitive repurchased 0.9 million shares worth $380 million in the second quarter — a signal that management views the current valuation as unduly depressed.

The Long-Term Picture Versus the Short-Term Noise

The gap between the current price and the 200-day moving average of 415.60 euros — roughly 22 percent above Monday's level — illustrates how much ground the stock needs to reclaim. Interestingly, the average analyst price target of 414.31 euros sits almost exactly at that technical benchmark. That convergence suggests analysts view the sell-off as an overreaction and expect a return to the historical trend once concerns about GLP-1 effects and healthcare policy subside.

The analyst community, however, is far from unanimous. Spain's Bankinter sees the recent decline as a buying opportunity, maintaining a buy rating with a 422.30 dollar target and citing Intuitive's quasi-monopolistic market position, roughly 80 percent recurring revenue, and EBITDA margins around 50 percent. HSBC struck a more cautious tone, downgrading to "Hold" with a 391 dollar target. The consensus sits at "Moderate Buy" with an average target of 509.02 dollars, though individual targets range from sell recommendations to over 600 dollars.

Institutional investors are equally divided. Rathbones Group, Sapient Capital, and BSN Capital Partners trimmed positions in the first quarter, while Defilade Capital Management expanded its stake by nearly half and Norges Bank built a new billion-dollar position. Insider selling — including by EVP Gary Loeb and SVP Iman Jeddi — adds another layer of ambiguity.

What Comes Next

The company's installed base of over 11,000 da Vinci systems generates roughly 85 percent recurring revenue from instruments, accessories, and service — a stable stream that cushions short-term procedure volatility. Competition is emerging, notably from China's Toumai system by MicroPort, but the structural demand story remains intact. The UK's NHS has committed to performing around 500,000 robotic surgeries annually by 2035.

The stock's trajectory now hinges on two variables: how quickly uncertainty around elective procedures dissipates, and how smoothly the da Vinci 5 rollout progresses over the coming quarters. The market has already delivered its verdict on the near term. The long-term verdict remains very much in play.